Correction:  Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidences

Vincenzo Quagliariello; Sabrina Rossetti; Carla Cavaliere; Rossella Di Palo; Elvira Lamantia; Luigi Castaldo; Flavia Nocerino; Gianluca Ametrano; Francesca Cappuccio; Gabriella Malzone; Micaela Montanari; Daniela Vanacore; Francesco Jacopo Romano; Raffaele Piscitelli; Gelsomina Iovane; Maria Filomena Pepe; Massimiliano Berretta; Carmine D’Aniello; Sisto Perdonà; Paolo Muto; Gerardo Botti; Gennaro Ciliberto; Bianca Maria Veneziani; Francesco De Falco; Piera Maiolino; Michele Caraglia; Maurizio Montella; Rosario Vincenzo Iaffaioli; Gaetano Facchini

doi:10.18632/oncotarget.20631

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidences

PDF | How to cite

Oncotarget. 2017; 8:62816-62816. https://doi.org/10.18632/oncotarget.20631

Metrics: PDF 2314 views | ?

Vincenzo Quagliariello^1,2,3,16, Sabrina Rossetti^1,2, Carla Cavaliere^1,4, Rossella Di Palo^1,5, Elvira Lamantia^1,6, Luigi Castaldo^1,7, Flavia Nocerino⁸, Gianluca Ametrano^1,5, Francesca Cappuccio^1,9, Gabriella Malzone^1,6, Micaela Montanari^1,10, Daniela Vanacore¹, Francesco Jacopo Romano¹, Raffaele Piscitelli^1,11, Gelsomina Iovane², Maria Filomena Pepe^1,6, Massimiliano Berretta^12,16, Carmine D’Aniello^1,13, Sisto Perdonà⁷, Paolo Muto⁵, Gerardo Botti⁶, Gennaro Ciliberto^14,17, Bianca Maria Veneziani¹⁰, Francesco De Falco⁹, Piera Maiolino¹¹, Michele Caraglia¹⁵, Maurizio Montella⁸, Rosario Vincenzo Iaffaioli^3,16 and Gaetano Facchini^1,2,16

¹ Progetto ONCONET2.0 - Linea progettuale 14 per l’implementazione della prevenzione e diagnosi precoce del tumore alla prostata e testicolo, Regione Campania, Italy
² Division of Medical Oncology, Department of Uro-Gynaecological Oncology , Istituto Nazionale Tumori ‘Fondazione G. Pascale’ - IRCCS, Naples, Italy
³ Medical Oncology, Abdominal Department, National Cancer Institute G. Pascale Foundation, Napoli, Italy
⁴ Department of Onco-Ematology Medical Oncology, S.G. Moscati Hospital of Taranto, Taranto, Italy
⁵ Radiation Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori ‘Fondazione Giovanni Pascale’ - IRCCS, Napoli, Italy
⁶ Pathology Unit, Istituto Nazionale Tumori “Fondazione G. Pascale”-IRCCS, Naples, Italy
⁷ Division of Urology, Department of Uro-Gynaecological Oncology , Istituto Nazionale Tumori ‘Fondazione G. Pascale’ - IRCCS, Naples, Italy
⁸ Epidemiology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori ‘Fondazione Giovanni Pascale’ - IRCCS, Napoli, Italy
⁹ Psicology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori ‘Fondazione Giovanni Pascale’ - IRCCS, Napoli, Italy
¹⁰ Department of Molecular Medicine and Medical Biotechnologies, University of Naples “Federico II”, Naples, Italy
¹¹ Pharmacy Unit, Istituto Nazionale Tumori, Istituto Nazionale Tumori-Fondazione G. Pascale, Naples, Italy
¹² Department of Medical Oncology, CRO Aviano, National Cancer Institute, Aviano, Italy
¹³ Division of Medical Oncology, A.O.R.N. dei COLLI “Ospedali Monaldi-Cotugno-CTO”, Napoli, Italy
¹⁴ Scientific Directorate, Istituto Nazionale per lo Studio e la Cura dei Tumori ‘Fondazione Giovanni Pascale’ - IRCCS, Napoli, Italy
¹⁵ Department of Biochemistry, Biophysics and General Pathology, Second University of Naples, Naples, Italy
¹⁶ Association for Multidisciplinary Studies in Oncology and Mediterranean Diet, Piazza Nicola Amore, Naples, Italy
¹⁷ Scientific Directorate, Istituto Nazionale per lo Studio e la Cura dei Tumori ‘Regina Elena’ - IRCCS, Roma, Italy

Published: September 05, 2017

This article has been corrected: The institutional affiliation information for Dr. Gennaro Ciliberto was updated to include affiliation #17.
The authors sincerely apologize for this oversight.

Original article: Oncotarget. 2017;8:30606-16. DOI:https://doi.org/10.18632/oncotarget.16725.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20631

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidences